Looking into the Nusantara Vaccine
All fields have a specific domain. Vaccines are the domain of medicine and health, so let the professionals in this field make the decisions.
The locally developed Nusantara vaccine candidate has suddenly become a controversial issue.
It started out simply. A team led by former health minister Agus Terawan is currently conducting local trials on a dendritic cell-based Covid-19 vaccine. The team has entered phase 2 trials, which is being carried out on a limited number of volunteers. Several parties have claimed this vaccine as “the work of the nation’s children” (homegrown).
Perhaps they are claiming it as a homegrown vaccine because it is called “Nusantara” (archipelago), another name for Indonesia. Due in part because of its name, several parties have expressed their support for the vaccine, including a number of public figures. Their support has been widely published in newspapers and on social media. Several House of Representatives (DPR) lawmakers have also volunteered for the trials. The reason is nationalism: locally developed products must be fully supported. The support has continued to flow.